Fortress Biotech (FBIO) Stock Statistics & Valuation Metrics

Fortress Biotech has a market cap or net worth of $86.60M. The enterprise value is $74.43M.

Fortress Biotech has 31,037,937 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fortress Biotech’s return on equity (ROE) is -0.66 and return on invested capital (ROIC) is -49.97%.

The current PE Ratio of Fortress Biotech is ―. Fortress Biotech’s PEG ratio is 0.03.

In the last 12 months, Fortress Biotech had revenue of 61.24M and earned -32.91M in profits. Earnings per share was -0.07.

In the last 12 months, operating cash flow was -100.36M and capital expenditures 0.00, giving a free cash flow of -100.36M billion.

Fortress Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Fortress Biotech upcoming earnings date is May 18, 2026, TBA (Confirmed).

Fortress Biotech as a current ratio of 2.49, with Debt / Equity ratio of 122.25%

In the past 12 months, Fortress Biotech has paid -620.00K in taxes.

Fortress Biotech EV to EBITDA ratio is -1.28, with an EV/FCF ratio of 0.00.

Fortress Biotech has $79.38M in cash and marketable securities with $67.22M in debt, giving a net cash position of $12.16M billion.

Gross margin is 65.83%, with operating margin of -114.67%, and net profit margin of -53.75%.

The average price target for Fortress Biotech is $17.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy